In Re Stanislaw R. Burzynski, M.D., and Burzynski Research Institute Inc.

989 F.2d 733, 1993 U.S. App. LEXIS 8434, 1993 WL 117784
CourtCourt of Appeals for the Fifth Circuit
DecidedApril 13, 1993
Docket92-2883
StatusPublished
Cited by98 cases

This text of 989 F.2d 733 (In Re Stanislaw R. Burzynski, M.D., and Burzynski Research Institute Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Stanislaw R. Burzynski, M.D., and Burzynski Research Institute Inc., 989 F.2d 733, 1993 U.S. App. LEXIS 8434, 1993 WL 117784 (5th Cir. 1993).

Opinion

BY THE COURT:

This case resembles one of those 1920’s automobiles that sometimes, even when my father was driving, would become stuck on a high center on a slightly improved road in east central Texas following a wet early spring. It seems to defy all efforts of both the district and circuit courts to bring about a final disposition. Certainly some of the blame rests with this court. In our first encounter we properly rejected the defense of privilege which the defendants had argued to defeat all the claims of the plaintiff. 967 F.2d 1063 (5th Cir.1992). We assumed implicitly that on remand the district court would either set aside at least some of its dismissals of various counts of the complaint without prejudice and find that a possible cause of action had been stated, or that all of its dismissals would be transformed into dismissals with prejudice. Our direction to the district court on remand to call for answers by the defendant was based on the first assumption (that some dismissals would be set aside) and did *737 not adequately consider the second (that all dismissals would be altered to “with prejudice.”)

It appears that another possibility existed. That is, for the district court to take no action with respect to prior dismissals without prejudice nor to call for answers by the defendant. At that point the plaintiffs sought a writ of mandamus to direct the district court to reinstate all the claims and call for answers thereto. We granted the writ to which the defendants have responded with a petition for rehearing.

We acknowledge error which was based upon the inadequate assumptions set forth above. What the parties want at this stage of the case is a decision with respect to each of the claims — whether its dismissals without prejudice were proper pending additional pleading, were improper because the claim does set forth a cause of action, or were improper because they should be dismissed with prejudice.

While we could lift the writ of mandamus and remand to the district court to make those determinations, the cause of expedited justice is better served by this court assuming this duty and then remanding to the district court such claims as may survive our review with proper instructions.

I.

ALLEGATIONS IN COMPLAINT

While the history of the alleged facts in this litigation appears in 967 F.2d 1063, supra, it will assist the reader to repeat them in substance at this time.

The plaintiff, Dr. Burzynski, operates the Burzynski Research Institute (BRI), and treats terminally ill cancer patients with a non-FDA approved treatment based on anti-neoplastins. Burzynski claims the treatment, while experimental, is still reimbursable under many insurance policies, including Aetna’s. The plaintiff alleges that in the mid-1980’s Aetna began denying rightful claims for this treatment in order to reduce its claims exposure.

One of Burzynski’s patients sued Aetna for reimbursement in August 1986. After she died, Burzynski intervened as assignee of her claims against Aetna. Burzynski v. Aetna Life Ins. Co., No. H-89-3976 (S.D.Tex. Apr. 1, 1992) [hereinafter Bur-zynski /]. This suit eventually ended in summary judgment for both sides on March 31, 1992. The plaintiff alleges that during the course of the lawsuit, the defendants committed many fraudulent acts.

First, Aetna hired a litigation consultant, Ms. Grace Monaco, who, according to the plaintiff, advised Aetna to file a RICO counterclaim against BRI which the defendants “knew ... had no basis in fact.” She also published a litigation “Alert” about the RICO counterclaim.

Second, during discovery in Burzynski I from January to March 1989, Aetna’s law firm, Hinshaw, Culbertson, Moelmann, Ho-ban & Fuller (Hinshaw Culbertson) sent a letter (Aetna/Hinshaw letter) to at least thirty five insurers. The ostensible purpose of the letter was a discovery request, however, it also served to dissuade other insurers from paying BRI claims. It urged them to stop paying BRI claims because the BRI treatment was “worthless,” was “mislabel[ed] as chemotherapy,” and was “unreimbursable.” In addition, the Aet-na/Hinshaw letter stated that Dr. Burzyn-ski’s claims forms contained misrepresentations and that he “defrauded” Aetna. The letter has an alarmist tone; it begins:

“This letter is sent to you as a result of an action filed by AEtna Life Insurance Company that may directly affect your company. You may have paid and may still be paying claims for cancer treatments of your insureds with an experimental substance used by Dr. Stanislaw Burzynski of Houston, Texas. AEtna Company has filed a civil RICO action against Dr. Burzynski. This letter is to warn you of potentially fraudulent claims for insurance reimbursement that may have been made to your company. ...” (emphasis added)

Most of the plaintiff’s claims against Aetna are based on this letter.

*738 Third, the plaintiff alleges that at some point after Burzynski I began, Aetna, through Monaco, created Emprise, Inc. Emprise ostensibly has no connection to Aetna, and its stated purpose is to provide objective reviews of alternative medical practitioners. However, Burzynski maintains that Emprise has the unstated purpose of generating negative reviews of alternative medical practitioners like Burzyn-ski in order to bolster Aetna’s position in denying coverage for this treatment. Bur-zynski also alleges that Monaco submitted false federal grant applications to gain federal funding for Emprise’s projects. He maintains that her applications did not disclose Emprise’s “real purpose,” its “close working connection” to Aetna, or Monaco’s position as an Aetna litigation consultant.

Fourth, during the course of discovery in Burzynski I, Aetna filed “false and misleading ex parte motions” in order to get privileged claims information from other insurers. The court awarded $11,100 in attorneys’ fees for this abusive and “almost unconscionable” discovery practice.

Fifth, also during Burzynski I, Monaco contacted researchers at the Medical College of Georgia (MCG) and, according to the plaintiff, tried unsuccessfully to dissuade them from continuing their research on antineoplastons. Consequently, in April 1989, the defendants served subpoenas and notices of depositions on MCG researchers to “intimidate” the scientists into dropping their antineoplaston research project and “without any intention of actually conducting discovery.”

Last, to “obtain[] leverage in its civil litigation,” Aetna “goaded” government agencies, in particular the local U.S. Attorney’s office, into investigating Burzynski and gave them false information about him.

II.

ANALYSIS OF CLAIMS

Conley v. Gibson, 355 U.S. 41, 47, 78 S.Ct.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Wen v. SanQuest, Inc.
N.D. Texas, 2025
D&T Partners v. Baymark Partners
98 F.4th 198 (Fifth Circuit, 2024)
Gabriel v. Outlaw
Fifth Circuit, 2023
Hudnall v. Smith
W.D. Texas, 2023
Vodicka v. Ermatinger
N.D. Texas, 2020
Labaty v. UWT, Inc.
121 F. Supp. 3d 721 (W.D. Texas, 2015)
Zastrow v. Houston Auto Imports Greenway Ltd.
789 F.3d 553 (Fifth Circuit, 2015)
Gordon v. Neugebauer
57 F. Supp. 3d 766 (N.D. Texas, 2014)
ISystems v. Victor Fu
Fifth Circuit, 2012
McPeters v. Edwards
806 F. Supp. 2d 978 (S.D. Texas, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
989 F.2d 733, 1993 U.S. App. LEXIS 8434, 1993 WL 117784, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-stanislaw-r-burzynski-md-and-burzynski-research-institute-inc-ca5-1993.